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Abstract 1 
Background: In England, rises in healthcare expenditure consistently outpace growth in both GDP 2 
and total public expenditure.  To ensure the National Health Service (NHS) remains financially 3 
sustainable, relevant data on healthcare expenditure are needed to inform decisions about which 4 
services should be delivered, by whom and in which settings.   5 
Methods: We analyse routine data on NHS expenditure in England over 9 years (2008/09 to 6 
2016/17).  To quantify the relative contribution of the different care settings to overall healthcare 7 
expenditure, we analyse trends in 14 healthcare settings under three broad categories: Hospital 8 
Based Care (HBC), Diagnostics and Therapeutics (D&T) and Community Care (CC). We exclude 9 
primary care and community mental health services settings due to a lack of consistent data. We 10 
employ a set of indices to aggregate diverse outputs and to disentangle growth in healthcare 11 
expenditure that is driven by activity from that due to cost pressures.  We identify potential drivers 12 
of the observed trends from published studies. 13 
Results: Over the 9-year study period, combined NHS expenditure on HBC, D&T and CC rose by 14 
50.2%.  Expenditure on HBC rose by 54.1%, corresponding to increases in both activity (29.2%) and 15 
cost (15.7%).  Rises in expenditure in inpatient (38.5%), outpatient (57.2%), and A&E (59.5%) settings 16 
were driven predominately by higher activity. Emergency admissions rose for both short-stay 17 
(45.6%) and long-stay cases (26.2%).  There was a switch away from inpatient elective care (which 18 
fell by 5.1%) and towards day case care (34.8% rise), likely reflecting financial incentives for same-19 
day discharges.  Growth in expenditure on D&T (155.2%) was driven by rises in the volume of high 20 
cost drugs (270.5%) and chemotherapy (110.2%).  Community prescribing grew by 45.2%, with costs 21 
falling by 24.4%.  Evidence on the relationship between new technologies and healthcare 22 
expenditure is mixed, but the fall in drug costs could reflect low generic prices, and the use of health 23 
technology assessment or commercial arrangements to inform pricing of new medicines. 24 
%OLQGHG0DQXVFULSW &OLFNKHUHWRDFFHVVGRZQORDG%OLQGHG0DQXVFULSW+(5B'ULYHUV+&'BPDQXVFULSWUHGDFWHG
&OLFNKHUHWRYLHZOLQNHG5HIHUHQFHV
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Conclusions: Aggregate trends in HCE mask enormous variation across healthcare settings. 25 
Understanding variation in activity and cost across settings is an important initial step towards 26 
ensuring the long-term sustainability of the NHS. 27 
 28 
Keywords: Healthcare expenditure, activity, cost, drivers, demographic pressures, technology 29 
Background 30 
Since the NHS was established in 1948, healthcare expenditure (HCE) has risen faster than both GDP 31 
and total public expenditure [1], a trend that is echoed in most OECD countries [2]. Between 2008 32 
and 2018, government expenditure on healthcare in England rose 25% in real terms, substantially 33 
more than the 13% real terms growth of the economy (GDP), and faster than every other category of 34 
government expenditure [3]. Rises in HCE are expected to continue in the medium to long-term even 35 
in the most conservative cost containment scenarios [2].  36 
Tackling the drivers of HCE is an enduring policy concern. Known drivers of overall growth in HCE 37 
include behaviours and lifestyle factors such as smoking, diet or physical activity [4], wealth and 38 
income effects [5] and prices [6]. There is evidence that demographic factors such as population 39 
ageing [7] are associated with rises in HCE.  Increases in the prevalence of multimorbidity is another 40 
well-ŬŶŽǁŶƉƌĞĚŝĐƚŽƌĂŶĚƐƚƵĚŝĞƐƐƵŐŐĞƐƚƚŚĂƚĐŽŵŽƌďŝĚŝƚŝĞƐŵĂǇďĞ ?ƐƵƉĞƌ-ĂĚĚŝƚŝǀĞ ?ŵĞĂŶŝŶŐƚŚĂƚ41 
the total cost of treating comorbid conditions is greater than the sum of the independent treatment 42 
costs of the underlying disease conditions [8]. More recently, macro-level studies of US expenditure 43 
have identified strong positive relationships between HCE and technological progress [5, 9], although 44 
the impact of new technology appears to vary across the distribution of expenditure [10]. 45 
Year-on-year real term rises in HCE, such as those observed within the English NHS, are considered 46 
to be one of the greatest challenges to its long-term fiscal sustainability [11]. To ensure the NHS 47 
remains financially viable, there is a need to understand how HCE may change in the future. This 48 
requires an oversight of historical trends in activity and cost across the whole system, and an 49 
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3 
appreciation of how these vary by healthcare setting and why. For example, a disaggregated analysis 50 
may reveal settings where costs are rising but activity is static, and this may be due to inefficiencies 51 
and/or waste. According to the OECD, one-fifth of health spending is wasteful; examples include 52 
missed appointments, avoidable admissions, duplication of services, delayed discharges and 53 
unnecessary expenditure on pharmaceuticals or procedures of limited clinical value [12].   54 
A ƐŝŵƉůĞĐŽŵƉĂƌŝƐŽŶŽĨƚƌĞŶĚƐĂĐƌŽƐƐŚĞĂůƚŚĐĂƌĞƐĞƚƚŝŶŐƐĐĂŶŝĚĞŶƚŝĨǇ “ƉƌĞƐƐƵƌĞƉŽŝŶƚƐ ?ĂŶĚŚĞůƉƚŽ55 
guide an exploration of potential drivers leading to improved performance. In addition, 56 
understanding how trends in expenditure, activity and cost vary across settings can inform spending 57 
reallocations within existing budgets, and improve workforce and budget planning.  58 
However, few studies of drivers of HCE have investigated how factors vary by care setting [3, 10, 13]. 59 
In addition, analyses of HCE trends are commonplace, but rarely disaggregate HCE growth into its 60 
constituent parts: activity and costs.  The purpose of this study is to address those gaps in the 61 
evidence base.  Our analyses provide an overview of the trends in expenditure and their breakdown 62 
in terms of cost and activity growth in three broad categories of care in the English NHS between 63 
2008/09 and 2016/17.  These categories together account for over 80% of total NHS spend. For each 64 
of the three categories, we also analyse trends in healthcare settings, and identify potential drivers 65 
for the observed trends drawing on evidence from the published literature.   66 
Methods 67 
To quantify the relative contribution of different settings to overall HCE, we analyse trends in 68 
expenditure, activity and costs for 14 healthcare settings of the English NHS.  The settings are 69 
grouped into three broad categories: Hospital Based Care (HBC), Diagnostics and Therapeutics (D&T) 70 
and Community Care (CC). The study period covers the financial years 2008/09 to 2016/17. Potential 71 
drivers for the observed trends are identified from evidence in the published literature.   72 
Table 1 shows which settings are included in each of the three categories, and the type of activity 73 
captured by each setting.  74 
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 75 
Table 1 Rates of growth in English NHS expenditure, activity and cost by healthcare setting 76 
Category Setting Type of Activity 
Total Growth  
2008/09 - 2016/17 
Mean year on year 
growth 
2008/09 - 2016/17 
   
Expendi
ture 
Activity Cost 
Expendi
ture 
Activity Cost 
Hospital 
Based Care 
(HBC) 
Inpatient Care 
FCE and Excess 
bed days 
38.6% 19.5% 16.0% 4.2% 2.3% 1.9% 
Outpatient 
Attendances and 
procedures 
57.2% 43.7% 9.4% 5.8% 4.7% 1.1% 
Accident & 
Emergency 
Attendances, 
investigations, 
treatments 
59.5% 30.2% 22.5% 6.0% 3.4% 2.6% 
Specialist Services Activity 34.8% 21.7% 10.8% 3.8% 2.5% 1.3% 
HBC weighted average growth 54.1% 29.2% 15.7% 5.6% 3.3% 1.8% 
Diagnostics 
and 
Therapeutic 
(D&T) 
Chemotherapy 
Treatment, 
procurement 
113.1% 110.2% 1.4% 10.0% 9.9% 0.4% 
Radiotherapy 
Treatment, 
preparation 
42.9% 72.1% -17.0% 4.6% 7.3% -2.2% 
High Cost Drugs Drug types 230.7% 270.5% -10.7% 16.7% 18.0% -1.2% 
Radiology Examinations  34.1% 39.8% -4.1% 3.8% 4.3% -0.5% 
Diagnostic Tests Tests 47.3% 59.0% -7.4% 5.1% 6.2% -0.8% 
Renal Dialysis Sessions 16.1% -1.0% 17.3% 1.9% -0.1% 2.0% 
D&T weighted average growth 155.2% 191.1% -7.0% 12.5% 14.4% -0.9% 
Community 
Care (CC) 
Community 
Prescribing 
Prescriptions 9.8% 45.2% -24.4% 1.2% 4.8% -3.4% 
Community 
Services 
Activity 35.0% 18.7% 13.8% 4.0% 2.4% 1.6% 
Optometry & 
Dentistry 
No. eye tests 
and dental 
procedures 
23.7% 7.2% 15.3% 2.7% 0.9% 1.8% 
Rehabilitation Activity 10.4% -2.3% 13.1% 1.5% -0.1% 1.6% 
CC weighted average growth 19.2% 34.7% -7.1% 2.3% 3.8% -0.9% 
 Total: all settings 50.2% 40.3% 7.1% 5.2% 4.3% 0.9% 
FCE: Finished Consultant Episode 
 77 
Two important settings, primary care and community mental healthcare, have been excluded from 78 
the analysis. This is due to a lack of historical official estimates of activity and cost for primary care 79 
and a lack of data for community mental health before 2011/12.   80 
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Data 81 
For 12 of the 14 settings, activity and cost data come from the National Schedule of Reference Costs 82 
[14]. NHS providers are required to report these administrative data every year in accordance with 83 
national costing guidance.  The cost of High Cost Drugs is included in the National Schedule of 84 
Reference Costs.  Data on community prescribing comes from the Prescription Cost Analysis (PCA) 85 
dataset [15],1 which provides details of the number of items and the net ingredient cost of 86 
prescriptions dispensed in the community.  Data on activities and costs of dentistry [16] and 87 
optometry [17] are provided by NHS Digital. 88 
Measuring Trends in Activity and Cost 89 
In order to disentangle the extent to which changes in HCE are driven by changes in activity and/or 90 
changes in unit cost we employ a set of indices. These are measures of change that allow the 91 
aggregation of diverse output items (such as Finished Consultant Episodes (FCEs), attendances, tests, 92 
prescriptions, etc.) in a single index and are useful for facilitating comparisons across categories and 93 
settings of healthcare.  These indices are routinely used in healthcare productivity analyses to 94 
measure the rate of growth of output [18, 19] . 95 
The Laspeyres Activity index is shown in Equation 1.  Cost is held constant to quantify the change in 96 
activity: the denominator is the product of each type of activity at time 0 and its associated cost at 97 
time 0; the numerator is the product of activity at time t and its cost at time 0. The Paasche Price 98 
index (Equation 2), works in a similar way, but activity is held constant to quantify the change in cost.  99 
The index for Total Expenditure incorporates both cost and activity changes (Equation 3). 100 
 101 
Equation 1 (i) Laspeyres Activity Index 102 
ሺܺ଴ǡ௧ሻ௅ ൌ  ? ௫ೕ೟௖ೕబ಻ೕసభ ? ௫ೕబ௖ೕబ಻ೕసభ                                                                                                                                              (1) 103 
                                                          
1 PCA data are supplied by the Prescription Pricing Authority via the NHS Digital Prescription Drugs Team.   
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 104 
Equation 2 (ii) Paasche Cost Index  105 ܥሺ଴ǡ௧ሻ௉ ൌ  ? ௫ೕ೟௖ೕ೟಻ೕసభ ? ௫ೕ೟௖ೕబ಻ೕసభ                                                                                                                                               (2) 106 
 107 
Equation 3 (iii) Total Expenditure Growth  108 ܧሺ଴ǡ௧ሻ ൌ ܥሺ଴ǡ௧ሻ௉ כ ሺܺ଴ǡ௧ሻ௅ ൌ  ? ௫ೕ೟௖ೕ೟಻ೕసభ ? ௫ೕబ௖ೕబ಻ೕసభ                                                                                                                  (3) 109 
 110 
In all three equations, ݔ௝  is the number of units of activity, i.e. FCEs, attendances, or treatments of 111 
type ݆, where ݆ ൌ  ?ǡ ǥ ǡ ܬ;  ௝ܿ is the unit cost of output ݆; and ݐ is time with ݐ ൌ  ? indicating the first 112 
period of the time series. The formulae are shown for a two-period index. To measure growth over a 113 
longer period of time, we use a chain index. In a chain index, the computation of the growth rates is 114 
performed over successive periods, then the product of these growth rates produces a chain series 115 
that uses the first period as reference (i.e. base year). Equation (4) shows the chain for the Laysperes 116 
activity index. 117 
 118 
Equation 4: Chain index for Laspeyres Activity  119 
ሺܺ଴ǡ்ሻ௅ ൌ  ሺܺ଴ǡ௧ሻ௅ ൈ ሺܺ௧ǡ௧ାଵሻ௅ ൈ ǥ ൈ ܺሺ୘ିଵǡ்ሻ௅                                                                                                        (4) 120 
 121 
We calculate these three indices for each of the three broad categories of care HBC, D&T and CC, 122 
and also for the 14 subcategories (settings).  We then plot growth rates using 2008/09 as the base 123 
year (i.e. 2008/09 indices are set equal to 100). Next, we identify relevant setting-specific evidence, 124 
drawn primarily from a previous review [3], to identify potential drivers of the observed trends.  All 125 
analyses were conducted using SAS Enterprise Guide 7.1. 126 
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Identifying Drivers of Trends in Activity and Cost 127 
To identify potential drivers for the observed trends we drew on a previous systematic review [3] 128 
that reported published studies by healthcare setting.   We selected studies from this review if they 129 
directly or indirectly provided evidence on potential drivers of trends from the empirical analyses.  130 
We drew on UK studies where possible, and included international evidence where UK evidence was 131 
lacking.  We also considered the role of relevant relevant regulatory schemes operating within the 132 
UK during our study period.     133 
Results 134 
Between 2008/09 and 2016/17, total current expenditure in the English NHS rose from £58.9 billion 135 
to £84.6 billion (Figure 1). NHS expenditure on the three care categories, HBC, D&T and CC, rose by 136 
50.2% and together account for over 82% of NHS expenditure. 137 
Figure 1 Total expenditure by care setting, £ million 138 
 139 
For the period 2008/09  ? 2016/17, Table 1 shows the growth in total expenditure, activity and cost  140 
and mean year-on-year growth, calculated using Equations (3), (1) and (2) respectively. The 141 
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information is provided at setting level as well as weighted averages for the three main groups. 142 
Average growth rates are weighted with respect to group size, measured by the relative share of 143 
total expenditure for each group. The table also shows the type of activity captured by each of the 144 
settings (e.g. FCEs, attendances, items, prescriptions, etc.).  145 
Figure 2 Trends in Expenditure, Activity and Costs growth: main activity groups 146 
 147 
Figure 2 shows the weighted average growth trends for total expenditure, activity and costs for the 148 
three broad categories of care HBC, D&T and CC. From 2008/09 to 2016/17, healthcare expenditure 149 
and activity rose every year in each of the three groups, with D&T exhibiting the greatest rate of 150 
increase. However, the D&T category accounts for approximately 7% of overall NHS spend and so its 151 
relative impact is less than that of HBC (which accounts for around 53% of total spend) and also 152 
below that of CC (22% of total spend). In terms of cost, there was a positive and increasing trend in 153 
HBC for the whole period, whereas the cost trends for D&T and CC were negative. These averages, 154 
however, conceal large variations across the different settings, which we consider below.  155 
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Hospital Based Care (HBC) 156 
Hospital based care (HBC) is the largest expenditure category and includes inpatient, outpatient, 157 
A&E and specialist services, accounting for over 50% of total English NHS expenditure. Overall, total 158 
expenditure grew by 54.1% from 2008/09 to 2016/17, which corresponds to a 29.2% growth in 159 
activity and a 15.7% growth in costs. In other words, around two-thirds of the rise in expenditure 160 
was due to increased activity and one-third to rises in cost. 161 
Inpatient care 162 
Figure 3 shows trends for each of the four HBC settings and a further breakdown for inpatient care 163 
which is the largest setting in terms of total value, accounting for over one-third of total NHS 164 
expenditure. Across the HBC settings, rises in expenditure ranged from 30% to 60% over the nine-165 
year study period.  166 
Figure 3 Trends in Expenditure, Activity and Costs for Hospital Based Care and Inpatient care 167 
 168 
On average, total inpatient expenditure rose by 4.2% annually. This translates into an increase from 169 
2008/09 to 2016/17 of 38.6% due to rises in both activity (19.5%) and cost (16.0%). There were 170 
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marked differences in growth rates for elective and non-elective care (Figure 2). Non-elective 171 
inpatient activity grew rapidly (45.6% for short stays and 26.2% for long-stays). In contrast, elective 172 
inpatient care fell by 5.1% over the period, whilst day cases rose by 34.8%. 173 
Cost trends for all the inpatient care sub-settings were similar with the rise in total cost ranging from 174 
15% to 19%. The exception was day cases where costs grew just over 10%.  175 
A plausible reason for the switch away from inpatient elective care to day cases is the Best Practice 176 
Tariff (BPT). Introduced in 2010, BPTs are national prices designed to incentivise high quality and 177 
cost-effective care  ? ?ďĞƐƚƉƌĂĐƚŝĐĞ ? ?and aim to reduce unexplained variation in clinical quality. The 178 
price differential between `best practice ? and `usual ? care creates an incentive for providers to shift 179 
from the latter to the former. A notable feature of BPTs is that they incentivise hospitals to admit, 180 
treat and discharge patients on the same day (when clinically appropriate) by paying a higher price 181 
for day care than for an overnight stay [20]. The fall in inpatient elective care activity (Figure 3) is 182 
more pronounced after 2011/12 and an empirical analysis has confirmed that most BPTs for elective 183 
care were effective in achieving this aim [20].  184 
Although demographic factors such as population ageing [21] are associated with rises in inpatient 185 
, ?ƚŚĞ ?ƌĞĚŚĞƌƌŝŶŐ ?ŚǇƉŽƚŚĞƐŝƐ proposes that time-to-death (TTD), rather than age, is the key 186 
demographic driver [22] though the interaction of the two factors is also important [23, 24]. 187 
However, TTD does not perform well as a predictor of spend on some nonlife threatening conditions 188 
such as long-term conditions and diseases treated predominantly with elective inpatient care [25]. It 189 
is self-evident that clinical factors, such as morbidities also drive inpatient HCE and indeed, TTD may 190 
itself be a proxy for morbidity [26]. A decomposition analysis of English inpatient data showed the 191 
prevalence of morbidities had a larger impact on inpatient costs than demographic drivers like age 192 
and sex [27]. The interaction between health status and mortality is also important when projecting 193 
HCE [28], and relates to the debate on compression and expansion of morbidity [26].  194 
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Outpatient care 195 
Outpatient figures, which capture care provided by NHS hospital trusts, show that the 57.2% growth 196 
in total expenditure was mainly driven by a 47.3% growth in activity whilst the increase in costs was 197 
relatively modest (9.4%). These findings are consistent with a Dutch investigation of individual HCE 198 
drivers [10], which revealed a move away from inpatient care coupled with a higher rate of day case 199 
admissions, shorter inpatient stays and greater use of outpatient clinics. A Spanish study [29] found 200 
per capita outpatient expenditure rose by 50% in real terms from 1998 to 2008, with the largest rise 201 
in people of working age. Evidence regarding the effect of age and TTD on outpatient utilisation and 202 
expenditure is mixed [13, 30]. A US analysis identified higher use of outpatient care was 203 
independently associated with unemployment and also with higher income, suggesting a non-linear 204 
relationship between utilisation and socioeconomic status [30]. However, socioeconomic status was 205 
not predictive of expenditure at the individual level.   206 
Accident & Emergency attendances 207 
The Accident & Emergency (A&E) setting comprises activity performed in Emergency Departments 208 
and other A&E services (e.g. ophthalmology, dental, NHS walk in centres). Overall, total expenditure 209 
rose by almost 60.0%, translating into a year-on-year rise of 6.0%. This annual rate of increase is at 210 
the top of the range cited by a recent systematic review of international studies [31], and in the case 211 
of England reflects rises in both activity (30.2%) and cost (22.5%). 212 
An Australian study [32] assessed changes in emergency department visits between 2010 and 2014. 213 
The rise in attendance rates per 1000 population exceeded population growth, with the highest rise 214 
observed in those aged 85 and over.  215 
The rise in A&E activity could be linked to reduced access to primary care services [31]. There is 216 
evidence that A&E is used as an out-of-hours substitute for primary care, and also that younger 217 
people perceive A&E as being generally more convenient [31]. Results from the GP (General 218 
Practice) Patient Survey for England show that the percentage of people reporting having seen a 219 
family doctor in the last three months fell by four percentage points between 2011/12 and 2016/17 220 
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[33]. A potential explanation is the increasing difficulty in booking an appointment, with the 221 
percentage of patients reporting easy access to GP surgery falling by eight percentage points over 222 
the same period [34]. These findings suggest that a lack of capacity in primary care could be an 223 
underlying reason for the rise in A&E activity. However, the lack of comprehensive data on primary 224 
care consultations prevents the computation of growth trends for that setting. 225 
Specialist services 226 
In the National Schedule of Reference Costs data,  ?specialist services ? comprises of activity in four 227 
distinct services: adult critical care, specialist palliative care, care for cystic fibrosis and  ? since 228 
2011/12  ? cancer multidisciplinary team meetings. Together, these services account for 229 
approximately 7.8% of HBC expenditure. Total expenditure rose by 34.8% from 2008/09 to 2016/17 230 
and breakdowns into a growth of 21.7% in activity and of 10.8% in cost.   231 
Diagnostics & Therapeutics (D&T) 232 
The Diagnostics and Therapeutics category encompasses six types of care: chemotherapy, 233 
radiotherapy, high cost drugs (HCD), radiology, diagnostic tests and renal dialysis. D&T accounted for 234 
approximately 7% of total NHS expenditure in England over the study period. Trends for D&T are 235 
shown in Figure 4.  236 
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Figure 4  Trends in Expenditure, Activity and Costs for Diagnostics & Therapeutics and Community Care 237 
 238 
D&T total expenditure grew by 255.2%, driven by an extraordinarily large growth in activity (291.1%) 239 
that was slightly offset by a reduction in the cost index (-7.05%).  Activity rose in all types of D&T 240 
care, with the exception of renal dialysis (-1.0%).  The largest activity growth was for HCD (270.5%) 241 
and chemotherapy (110.2%). Although the patient classification system (Healthcare Resource 242 
Groups or HRGs) has been fairly stable since 2013/14, the HRGs used to classify chemotherapy, 243 
radiotherapy, and HCD have been subject to substantial revision over time [33]. Better recording of 244 
activity and the introduction of new coding that spilt activity in more than one HRG (when previously 245 
the activity was captured by a single HRG) could overstate the observed increase in activity. 246 
Nonetheless, the drivers of large rises in activity, and relatively small increases in costs, for HCDs and 247 
chemotherapy are worth considering. In England, the availability of new technologies is influenced 248 
by appraisals of cost-effectiveness by the National Institute for Health and Care Excellence (NICE) 249 
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[35]. NICE assesses the value of many HCDs, a category that captures drugs2 whose cost is 250 
disproportionally high and that are used to treat a limited number of patients. Although NICE 251 
assessments inform value-based pricing, NICE does not negotiate the price of new drugs.  Over our 252 
study period, prices of branded medicines were regulated by a voluntary scheme known as the 253 
Pharmaceutical Price Regulation Scheme (PPRS).  The aims of the scheme were to keep expenditure 254 
ŽŶďƌĂŶĚĞĚŵĞĚŝĐŝŶĞƐǁŝƚŚŝŶ ?ĂĨĨŽƌĚĂďůĞůŝŵŝƚƐ ?, whilst improving access to new medicines and 255 
encouraging innovation [36].  The scheme limited the growth of NHS spend on new drugs, included 256 
pricing flexibilities such as Patient Access Schemes (i.e. commercial arrangements), and allowed 257 
manufacturers to offer local discounts to hospitals.  Therefore, the PPRS is a potential explanation 258 
for the observed trends in HCD activity and costs.  The Cancer Drug Fund (CDF), which covers the 259 
costs of certain drugs that are not recommended by NICE due to their lack of proven cost-260 
effectiveness, was introduced in England in 2011 [37]. The CDF is another plausible driver of the 261 
accelerated growth in the volume of HCD observed from 2012/13 onwards.  262 
For settings with negative trends in total cost, values ranged from -4.1% (radiology) to -17.4% 263 
(radiotherapy). Growth in the cost of chemotherapy was small but positive (1.4%) whereas costs for 264 
renal dialysis rose by 17.3%. The reason for the rise in the costs of renal dialysis is unclear, but could 265 
be linked to higher levels of multimorbidity [38]. There is also some evidence of positive and linear 266 
relationships between TTD and expenditure on D&T [39], which suggests frailty may also be a factor. 267 
Other important drivers of HCE are the introduction of new health technologies and institutional 268 
characteristics. Evidence from the Netherlands showed that structural factors such as changes in 269 
regulation, policy and greater use of new technologies increased costs particularly for the highest 270 
cost patients [10]. 271 
                                                          
2 The drugs listed vary by year, but include treatments for cancer, hepatitis C, HIV, transplant 
patients, juvenile arthritis and cystic fibrosis among others. 
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Community Care (CC) 272 
Community care encompasses community prescribing, community services, optometry, dentistry, 273 
and rehabilitation, and accounts for over one-fifth of the total expenditure in the English NHS. 274 
Trends for CC are shown in Figure 4. Overall growth in CC expenditure, activity and cost were 19.2%, 275 
34.7% and -7.1% respectively, but conceal large variations across settings.  276 
Community prescribing, the largest setting as a share of CC expenditure (55%), exhibits a modest 277 
total expenditure growth of 9.8% comprising a 45.2% total activity growth and a fall in cost of 24.4% 278 
between 2008/09 and 2016/17. The reduction in pharmaceutical prices may reflect the relatively 279 
low price of generics during our study period [40], the Pharmaceutical Price Regulation Scheme [36], 280 
and the use of health technology assessment to inform the price of new branded medicines [41, 42]. 281 
Our findings contrast with the findings from a Dutch study [10] which found that prescribing 282 
expenditure rose by 69% from 2004 to 2013. The authors found that the increase in expenditure was 283 
driven principally by structural shifts such as technological progress (e.g. the highest cost cases were 284 
treated with even more expensive drugs). Changes in the distribution of determinants, such as 285 
population ageing and a rise in the number of outpatient visits, played a lesser role but were also 286 
important explanatory factors. For community prescribing, proximity to death might be a more 287 
important driver than age as there is evidence that the effects of age on prescribing expenditure are 288 
smaller when models control for TTD [13, 43, 44]. Gender also seems to be a driver of 289 
pharmaceutical expenditure: there is evidence that females in all age groups incur higher 290 
expenditure [29] and receive more prescriptions [13]. 291 
With regard to community services and rehabilitation, activity rose by 35.0% and 10.4% respectively, 292 
with steeper rates of increase from 2013/14 onwards. On average, costs rose by around 13% to 14% 293 
across the period for both settings. The cost of optometry and dentistry rose by 15%, equating to a 294 
mean year-on-year rate of 1.8%, whereas the rise in activity was lower: 7.2% overall, with an 295 
average annual rise of 0.9%. 296 
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Discussion 297 
This study of trends in English HCE reveals how much was due to changes in the activity and how 298 
much was due to cost, and how this varied across care settings. Overall, HCE grew by approximately 299 
50% over the nine year study period (2008/09 to 2016/17) driven mainly by a 40% rise in activity, 300 
and a comparatively modest growth in costs (7%). Aggregate figures conceal large variations across 301 
settings. Specifically, total expenditure on Hospital Based Care (HBC) rose by 54%, spend on 302 
Diagnostics and Therapeutics (D&T) rose by 155%, and spend on Community Care (CC) grew by 19%. 303 
The rise in HBC expenditure was driven mainly by a rise in activity (29%) but also by a considerable 304 
growth in costs (16%).  305 
In the majority of the individual settings, with the exception of renal dialysis and rehabilitation, 306 
growth in expenditure was driven primarily by growth in activity. This finding accords with 307 
EĞǁŚŽƵƐĞ ?ƐĂƌŐƵŵĞŶƚƚŚĂƚƚĞĐŚŶŽůŽŐŝĐĂůĐŚĂŶŐĞ-  “ƚŚĞŵĂƌĐŚŽĨƐĐŝĞŶĐĞ ? ? increases the capacity of 308 
healthcare systems to supply healthcare [45] and is a major factor driving rising healthcare 309 
expenditure.  However, whilst there is evidence of a strong, positive relationship between new 310 
technologies and aggregate HCE [5, 9], the relationship at the individual level is complex and 311 
dynamic, and varies depending on the context and particular type of technology [46]. A better 312 
understanding how new technology influences the process of care therefore appears pivotal in 313 
determining its impact on HCE and so the financial viability of the future NHS.  314 
HBC is the largest setting within the NHS in terms of overall spend, and also exhibited the largest rise 315 
in cost. This points to the need to understand the reasons why cost pressures appear greater in HBC, 316 
and future research could examine whether these are due to labour costs, capital costs or factors 317 
outside of the HBC setting. Faced with an ageing population and with utilisation rates predicted to 318 
continue to increase, greater efficiency may be called for. Alternatively, an improvement in NHS 319 
productivity (i.e. the ratio of output growth over input growth) could help alleviate financial 320 
pressures. Accounting for 45% of the total input expenditure in 2016/17 [33], labour is the largest 321 
single input in the NHS.  Therefore, improvements in the labour productivity, such as through 322 
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reductions in the avoidable use of bank and agency staff, changes in the skill-mix of labour (perhaps 323 
via digitally enabled care), or stronger preventative care in ambulatory settings, have potential to 324 
curb the growth in HCE.  325 
The NHS Long Term Plan [47] recognises the pressures faced by emergency services.  Various 326 
remedial measures are proposed, including £4.5 billion new investment in primary care and 327 
community care, and the expansion and reform of urgent and emergency care services including the 328 
ŶĂƚŝŽŶĂůŝŵƉůĞŵĞŶƚĂƚŝŽŶŽĨ ?ƵƌŐĞŶƚƚƌĞĂƚŵĞŶƚĐĞŶƚƌĞƐ ?and the roll-ŽƵƚŽĨ ?ƐĂŵĞĚĂǇĞŵĞƌŐĞŶcy 329 
ĐĂƌĞ ?ĂƐĂŶĂůƚĞƌŶĂƚŝǀĞƚŽĂŶŽǀĞƌŶŝŐŚƚĞŵĞƌŐĞŶĐǇĂĚŵŝƐƐŝŽŶ. 330 
Regarding individual drivers, the prevalence of disability, morbidity and multimorbidity appear 331 
critical in determining future trends in HCE. International studies have documented changes in the 332 
patterns of disability and chronic morbidity, with the age of onset of these conditions occurring later 333 
in life (compression of morbidity) [26]. However, the effect on individual lifetime HCE will depend on 334 
changes in life-expectancy, and how much of any extra life is disability- or morbidity-free. For 335 
example, if individuals live longer and have more years in ill-health (expansion of morbidity) then 336 
HCE would likely be higher. Even if morbidity is compressed (fewer years in ill-health), if the 337 
complexity of their health needs increases then HCE may also rise. The net impact on aggregate 338 
(population level) HCE will also depend on changes in the age structure of the population.  339 
The data used in this study is at an aggregate level. We describe trends in activity, cost and 340 
expenditure but can only conjecture how the demand drivers identified in the literature may impact 341 
those trends. No causal link is claimed. Moreover, the heterogeneity of the available studies (see [3] 342 
for a comprehensive review) makes it very difficult to compare their findings in a robust way.  For 343 
example, there are large gaps in the evidence for many care settings, and a dearth of studies from 344 
the UK.  In the future the availability of patient level cost data (PLICS3) appears a promising dataset 345 
for a more comprehensive study of the HCE drivers at the individual level.   346 
                                                          
3 PLICS: Patient Level Information Costing Data Set. 
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Conclusions 347 
Our contribution is to shed light on how much each type of setting has contributed to past trends in 348 
healthcare expenditure growth and how much of that growth is due to changes in the costs of care 349 
or due to changes in the level of activity. Our analyses demonstrate that aggregate trends in HCE 350 
mask enormous variation across healthcare settings. This information is useful for policy makers in 351 
charge of planning, because it clarifies whether cost pressures or rising activity are the principal 352 
reason for rising HCE in the different healthcare settings. Nonetheless, there is a lack of relevant 353 
studies for the NHS on how individual drivers affect HCE. Further research is needed to discern the 354 
impact of those on cost and to model future healthcare demand.  355 
List of abbreviations 356 
A&E accident and emergency (department) 357 
BPT Best Practice Tariff 358 
CC Community Care 359 
CDF Cancer Drug Fund 360 
D&T Diagnostics and therapeutics 361 
FCE Finished Consultant Episode 362 
GDP Gross Domestic Product 363 
GP general practice 364 
HBC Hospital Based Care 365 
HCE healthcare expenditure 366 
HRG Healthcare Resource Group 367 
NHS National Health Service 368 
NICE National Institute for Health and Care Excellence 369 
OECD Organisation for Economic Co-operation and Development 370 
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PPRS Pharmaceutical Price Regulation Scheme 371 
TTD time-to-death 372 
US United States 373 
  374 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
20 
References 375 
1. Harker, R., NHS funding and expenditure. House of Commons Library, 2012. Standard Note 376 
SN/SG/724: p. 11. 377 
2. Organisation for Economic Co-operation and Development (OECD), Fiscal sustainability of 378 
health systems: bridging health and finance perspectives. 2015: OECD. 379 
3. Mason, A., I. Rodriguez Santana, M.J. Aragon Aragon, N. Rice, M.J. Chalkley, R. Wittenberg, 380 
et al., Drivers of Health Care Expenditure, in CHE Research Paper 169. 2019: Centre for 381 
Health Economics, University of York. p. 56. 382 
4. Hernandez-Aceituno, A., R.F. Perez-Tasigchana, P. Guallar-Castillon, E. Lopez-Garcia, F. 383 
Rodriguez-Artalejo, and J.R. Banegas, Combined Healthy Behaviors and Healthcare Services 384 
Use in Older Adults. American Journal of Preventive Medicine, 2017. 53(6): p. 872-881. 385 
5. Martin, J.J.M., M.P. Lopez del Amo Gonzalez, and M.D.C. Garcia, Review of the Literature on 386 
the Determinants of Healthcare Expenditure. Applied Economics, 2011. 43(1-3): p. 19-46. 387 
6. Astolfi, R., L. Lorenzoni, and J. Oderkirk, Informing policy makers about future health 388 
spending: A comparative analysis of forecasting methods in OECD countries. Health Policy, 389 
2012. 107(1): p. 1-10. 390 
7. Hartwig, J. and J.E. Sturm, Testing the Grossman model of medical spending determinants 391 
with macroeconomic panel data. European Journal of Health Economics, 2018. 16: p. 16. 392 
8. Cortaredona, S. and B. Ventelou, The extra cost of comorbidity: multiple illnesses and the 393 
economic burden of non-communicable diseases. BMC Medicine, 2017. 15(1): p. 216. 394 
9. Murthy, V.N.R. and N. Ketenci, Is technology still a major driver of health expenditure in the 395 
United States? Evidence from cointegration analysis with multiple structural breaks. 396 
International Journal of Health Economics and Management, 2017. 17(1): p. 29-50. 397 
10. de Meijer, C., O. O'Donnell, M. Koopmanschap, and E. van Doorslaer, Health expenditure 398 
growth: looking beyond the average through decomposition of the full distribution. Journal 399 
of Health Economics, 2013. 32(1): p. 88-105. 400 
11. Licchetta, M. and M. Stelmach, Fiscal sustainability and public spending on health. OBR Fiscal 401 
sustainability analytical paper, 2016: p. 45. 402 
12. Organisation for Economic Co-operation and Development (OECD) and European Union, 403 
Health at a Glance: Europe 2018. 2018. 404 
13. Hakkinen, U., P. Martikainen, A. Noro, E. Nihtila, and M. Peltola, Aging, health expenditure, 405 
proximity to death, and income in Finland. Health Economics, Policy, & Law, 2008. 3(Pt 2): p. 406 
165-95. 407 
14. Department of Health, NHS England, and NHS Improvement, Reference Cost Collection: 408 
National Schedule of Reference Costs, 2016-17 - NHS trusts and NHS foundation trusts. 2017, 409 
NHS Improvement: London. 410 
15. NHS Digital Prescribing and Medicine Team, Prescription Cost Analysis - England, 2016. 2017, 411 
NHS Digital: Leeds. 412 
16. NHS Digital Primary Care Domain, NHS Dental Statistics for England - 2016-17. 2017, NHS 413 
Digital: Leeds. 414 
17. NHS Digital Primary Care Domain, General Ophthalmic Services activity statistics - England, 415 
year ending 31 March 2017. 2017, NHS Digital: Leeds. 416 
18. Bojke, C., A. Castelli, K. Grasic, D.D.H. Howdon, A.D. Street, and I.D.L.N. Rodriguez Santana, 417 
Productivity of the English NHS: 2014/15 update. CHE Research Paper 146. 2017, Centre for 418 
Health Economics, University of York: York, UK. p. 1-81. 419 
19. Castelli, A., D. Dawson, H. Gravelle, and A. Street, Improving the measurement of health 420 
system output growth. Health Economics, 2007. 16(10): p. 1091-1107. 421 
20. 'ĂƵŐŚĂŶ ?: ? ?E ?'ƵƚĂĐŬĞƌ ?< ?'ƌĂƓŝē ?E ?<ƌĞŝĨ ?> ?^ŝĐŝůŝĂŶŝ ?ĂŶĚ ?^ƚƌĞĞƚ ?Paying for efficiency: 422 
Incentivising same-day discharges in the English NHS. Journal of Health Economics, 2019. 68: 423 
p. 102226. 424 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
21. Hartwig, J., What drives health care expenditure?--Baumol's model of 'unbalanced growth' 425 
revisited. Journal of Health Economics, 2008. 27(3): p. 603-23. 426 
22. Zweifel, P., S. Felder, and M. Meiers, Ageing of population and health care expenditure: a red 427 
herring? Health Economics, 1999. 8(6): p. 485-96. 428 
23. Geue, C., A. Briggs, J. Lewsey, and P. Lorgelly, Population ageing and healthcare expenditure 429 
projections: new evidence from a time to death approach. European Journal of Health 430 
Economics, 2014. 15(8): p. 885-96. 431 
24. Geue, C., P. Lorgelly, J. Lewsey, C. Hart, and A. Briggs, Hospital expenditure at the end-of-life: 432 
what are the impacts of health status and health risks? PLoS ONE [Electronic Resource], 433 
2015. 10(3): p. e0119035. 434 
25. Wong, A., P.H. van Baal, H.C. Boshuizen, and J.J. Polder, Exploring the influence of proximity 435 
to death on disease-specific hospital expenditures: a carpaccio of red herrings. Health 436 
Economics, 2011. 20(4): p. 379-400. 437 
26. Howdon, D. and N. Rice, Health care expenditures, age, proximity to death and morbidity: 438 
Implications for an ageing population. J Health Econ, 2018. 57: p. 60-74. 439 
27. Rice, N. and M.J.M. Aragon Aragon, The determinants of health care expenditure growth. 440 
CHE Research Paper 156. 2018, Centre for Health Economics, University of York: York, UK. 441 
28. Wouterse, B., B.R. Meijboom, and J.J. Polder, The relationship between baseline health and 442 
longitudinal costs of hospital use. Health Economics, 2011. 20(8): p. 985-1008. 443 
29. Blanco-Moreno, A., R.M. Urbanos-Garrido, and I.J. Thuissard-Vasallo, Public healthcare 444 
expenditure in Spain: measuring the impact of driving factors. Health Policy, 2013. 111(1): p. 445 
34-42. 446 
30. Frees, E.W., J. Gao, and M.A. Rosenberg, Predicting the Frequency and Amount of Health 447 
Care Expenditures. North American Actuarial Journal, 2011. 15(3): p. 377-92. 448 
31. Coster, J.E., J.K. Turner, D. Bradbury, and A. Cantrell, Why Do People Choose Emergency and 449 
Urgent Care Services? A Rapid Review Utilizing a Systematic Literature Search and Narrative 450 
Synthesis. Academic emergency medicine : official journal of the Society for Academic 451 
Emergency Medicine, 2017. 24(9): p. 1137-1149. 452 
32. Dinh, M.M., S. Berendsen Russell, K.J. Bein, D. Chalkley, D. Muscatello, R. Paoloni, et al., 453 
Understanding drivers of Demand for Emergency Service Trends in Years 2010-2014 in New 454 
South Wales: An initial overview of the DESTINY project. Emergency Medicine Australasia, 455 
2016. 28(2): p. 179-86. 456 
33. Castelli, A., M.J. Chalkley, J.M. Gaughan, M.L. Pace, and I. Rodriguez Santana, Productivity of 457 
the English National Health Service: 2016/17 update. CHE Research Paper 163. 2019, Centre 458 
for Health Economics, University of York: York, UK. p. 77. 459 
34. Castelli, A., M. Chalkley, and I.D.L.N. Rodriguez Santana, Productivity of the English National 460 
Health Service: 2015/16 update.  CHE Research Paper 152, in 2015/16 update. 2018, Centre 461 
for Health Economics, University of York: York, UK. p. 1-78. 462 
35. Mason, A.R. and M.F. Drummond, Public funding of new cancer drugs: Is NICE getting 463 
nastier? European Journal of Cancer, 2009. 45(7): p. 1188-92. 464 
36. Department of Health and Association of the British Pharmaceutical Industry, The 465 
Pharmaceutical Price Regulation Scheme 2014 2013, Department of Health: London. p. 135. 466 
37. Wood, E.M. and D.A. Hughes, The New and Non-Transparent Cancer Drugs Fund. 467 
PharmacoEconomics, 2020. 38(1): p. 1-4. 468 
38. Dieleman, J.L., R. Baral, E. Johnson, A. Bulchis, M. Birger, A.L. Bui, et al., Adjusting health 469 
spending for the presence of comorbidities: an application to United States national inpatient 470 
data. Health Economics Review, 2017. 7(1): p. 30. 471 
39. Moorin, R., D. Gibson, D. Holman, and D. Hendrie, The contribution of age and time-to-death 472 
on health care expenditure for out-of-hospital services. Journal of Health Services & Research 473 
Policy, 2012. 17(4): p. 197-205. 474 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
40. National Audit Office, Investigation into NHS spending on generic medicines in primary care. 475 
HC 1122 SESSION 2017ʹ2019. 2018, National Audit Office: London. 476 
41. Drummond, M. and A. Towse, Is rate of return pricing a useful approach when value-based 477 
pricing is not appropriate? The European Journal of Health Economics, 2019. 20(7): p. 945-478 
948. 479 
42. NHS England, NHS Commercial Frameworkfor Medicines: Draft for Engagement (version 1). 480 
2019. p. 33. 481 
43. Moore, P.V., K. Bennett, and C. Normand, The importance of proximity to death in modelling 482 
community medication expenditures for older people: evidence from New Zealand. Applied 483 
Health Economics & Health Policy, 2014. 12(6): p. 623-33. 484 
44. Thiebaut, S.P., T. Barnay, and B. Ventelou, Ageing, Chronic Conditions and the Evolution of 485 
Future Drugs Expenditure: A Five-Year Micro-simulation from 2004 to 2029. Applied 486 
Economics, 2013. 45(13-15): p. 1663-72. 487 
45. Newhouse, J.P., Medical Care Costs: How Much Welfare Loss? Journal of Economic 488 
Perspectives, 1992. 6(3): p. 3-21. 489 
46. Sorenson, C., M. Drummond, and B. Bhuiyan Khan, Medical technology as a key driver of 490 
rising health expenditure: disentangling the relationship. Clinicoeconomics & Outcomes 491 
Research, 2013. 5: p. 223-34. 492 
47. NHS England, NHS Long Term Plan. 2019. p. 136. 493 
 494 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
